|
1
|
Mishel MH, Hostetter T, King B and Graham
V: Predictors of psychosocial adjustment in patients newly
diagnosed with gynecological cancer. Cancer Nurs. 7:291–299. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Linden W, Vodermaier A, Mackenzie R and
Greig D: Anxiety and depression after cancer diagnosis: prevalence
rates by cancer type, gender, and age. J Affect Disord.
141:343–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brintzenhofe-Szoc KM, Levin TT, Li Y,
Kissane DW and Zabora JR: Mixed anxiety/depression symptoms in a
large cancer cohort: prevalence by cancer type. Psychosomatics.
50:383–391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colleoni M, Mandala M, Peruzzotti G, et
al: Depression and degree of acceptance of adjuvant cytotoxic
drugs. Lancet. 356:1326–1327. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pinquart M and Duberstein PR: Depression
and cancer mortality: a meta-analysis. Psychol Med. 40:1797–1810.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Satin JR, Linden W and Phillips MJ:
Depression as a predictor of disease progression and mortality in
cancer patients: a meta-analysis. Cancer. 115:5349–5361. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lemon J, Edelman S and Kidman AD:
Perceptions of the “Mind-Cancer” Relationship Among the Public,
Cancer Patients, and Oncologists. J Psychosoc Oncol. 21:43–58.
2004. View Article : Google Scholar
|
|
8
|
American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders. 5th edition.
American Psychiatric Publishing; Arlington, VA: 2013
|
|
9
|
Sneeuw KCA, Aaronson NK, van Wouwe MCC, et
al: Prevalence and screening of psychiatric disorder in patients
with early stage breast cancer. Qual Life Res. 2:50–51. 1993.
|
|
10
|
Okamura M, Yamawaki S, Akechi T, et al:
Psychiatric disorders following first breast cancer recurrence:
prevalence, associated factors and relationship to quality of life.
Jpn J Clin Oncol. 35:302–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ciaramella A and Poli P: Assessment of
depression among cancer patients: the role of pain, cancer type and
treatment. Psychooncology. 10:156–165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ng CG, Boks MP, Zainal NZ and de Wit NJ:
The prevalence and pharmacotherapy of depression in cancer
patients. J Affect Disord. 131:1–7. 2011. View Article : Google Scholar
|
|
13
|
Allen R, Newman SP and Souhami RL: Anxiety
and depression in adolescent cancer: findings in patients and
parents at the time of diagnosis. Eur J Cancer. 33:1250–1255. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
von Essen L, Enskär K, Kreuger A, et al:
Self-esteem, depression and anxiety among Swedish children and
adolescents on and off cancer treatment. Acta Paediatr. 89:229–236.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boyes AW, Girgis A, Zucca AC and
Lecathelinais C: Anxiety and depression among long-term survivors
of cancer in Australia: results of a population-based survey. Med J
Aust. 190:S94–S98. 2009.PubMed/NCBI
|
|
16
|
Spiegel D, Sands S and Koopman C: Pain and
depression in patients with cancer. Cancer. 74:2570–2578. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akechi T, Nakano T, Akizuki N, et al:
Somatic symptoms for diagnosing major depression in cancer
patients. Psychosomatics. 44:244–248. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pasquini M, Speca A, Mastroeni S, et al:
Differences in depressive thoughts between major depressive
disorder, IFN-alpha-induced depression, and depressive disorders
among cancer patients. J Psychosom Res. 65:153–156. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Musselman DL, Miller AH, Porter MR, et al:
Higher than normal plasma interleukin-6 concentrations in cancer
patients with depression: preliminary findings. Am J Psychiatry.
158:1252–1257. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nadjar A, Bluthé RM, May MJ, et al:
Inactivation of the cerebral NFkappaB pathway inhibits
interleukin-1beta-induced sickness behavior and c-Fos expression in
various brain nuclei. Neuropsychopharmacology. 30:1492–1499. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zigmond AS and Snaith RP: The hospital
anxiety and depression scale. Acta Psychiatr Scand. 67:361–370.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jehn CF, Kuehnhardt D, Bartholomae A, et
al: Biomarkers of depression in cancer patients. Cancer.
107:2723–2729. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bianchi ME: DAMPs, PAMPs and alarmins: all
we need to know about danger. J Leukoc Biol. 81:1–5. 2007.
View Article : Google Scholar
|
|
24
|
Aggarwal BB, Shishodia S and Sandur SK:
Inflammation and cancer: how hot is the link? Biochem Pharmacol.
72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bierhaus A, Wolf J, Andrassy M, et al: A
mechanism converting psychosocial stress into mononuclear cell
activation. Proc Natl Acad Sci USA. 100:1920–1925. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szabo S, Gould TD and Manji HK:
Introduction to neurotransmitters, receptors, signal transduction,
and second messengers in psychiatric disorders. The American
Psychiatric Publishing Textbook of Psychopharmacology. Schatzberg
AF and Nemeroff CB: 3rd edition. American Psychiatric Publishing;
Washington DC: pp. 3–51. 2004
|
|
27
|
Raison CL, Capuron L and Miller AH:
Cytokines sing the blues: inflammation and the pathogenesis of
depression. Trends Immunol. 27:24–31. 2006. View Article : Google Scholar
|
|
28
|
Zhu CB, Carneiro AM, Dostmann WR, Hewlett
WA and Blakely RD: p38 MAPK activation elevates serotonin transport
activity via a trafficking-independent, protein phosphatase
2A-dependent process. J Biol Chem. 280:15649–15658. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Holsboer F and Ising M: Central CRH system
in depression and anxiety - evidence from clinical studies with
CRH1 receptor antagonists. Eur J Pharmacol. 583:350–357. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duman RS and Monteggia LM: A neurotrophic
model for stress-related mood disorders. Biol Psychiatry.
59:1116–1127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Felger JC, Mun J, Kimmel HL, Nye JA, et
al: Chronic interferon-α decreases dopamine 2 receptor binding and
striatal dopamine release in association with anhedonia-like
behaviour in nonhuman primates. Neuropsychopharmacology.
38:2179–2187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Felger JC, Li L, Marvar PJ, et al:
Tyrosine metabolism during interferon-alpha administration:
association with fatigue and CSF dopamine concentrations. Brain
Behav Immun. 31:153–160. 2013. View Article : Google Scholar :
|
|
33
|
Dantzer R, O’Connor JC, Freund GG, et al:
From inflammation to sickness and depression: when the immune
system subjugates the brain. Nat Rev Neurosci. 9:46–56. 2008.
View Article : Google Scholar
|
|
34
|
DeMyer MK, Shea PA, Hendrie HC and
Yoshimura NN: Plasma tryptophan and five other amino acids in
depressed and normal subjects. Arch Gen Psychiatry. 38:642–646.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Myint AM and Kim YK: Cytokine-serotonin
interaction through IDO: a neurodegeneration hypothesis of
depression. Med Hypotheses. 61:519–525. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sapolsky RM: The possibility of
neurotoxicity in the hippocampus in major depression: a primer on
neuron death. Biol Psychiatry. 48:755–765. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pace TW, Hu F and Miller AH:
Cytokine-effects on glucocorticoid receptor function: relevance to
glucocorticoid resistance and the pathophysiology and treatment of
major depression. Brain Behav Immun. 21:9–19. 2007. View Article : Google Scholar
|
|
38
|
Pavlov VA and Tracey KJ: The cholinergic
anti-inflammatory pathway. Brain Behav Immun. 19:493–499. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Besedovsky HO and del Rey A:
Immune-neuro-endocrine interactions: facts and hypotheses. Endocr
Rev. 17:64–102. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang X: Interleukin 1alpha (IL-1alpha)
induced activation of p38 mitogen-activated kinase inhibits
glucocorticoid receptor function. Mol Psychiatry. 9:65–75. 2004.
View Article : Google Scholar
|
|
41
|
Raison CL and Miller AH: When not enough
is too much: the role of insufficient glucocorticoid signaling in
the pathophysiology of stress-related disorders. Am J Psychiatry.
160:1554–1565. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Patten SB and Barbui C: Drug-induced
depression: a systematic review to inform clinical practice.
Psychother Psychosom. 73:207–215. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fann JR, Thomas-Rich AM, Katon WJ, et al:
Major depression after breast cancer: a review of epidemiology and
treatment. Gen Hosp Psychiatry. 30:112–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu L, Fiorentino L, Natarajan L, et al:
Pre-treatment symptom cluster in breast cancer patients is
associated with worse sleep, fatigue and depression during
chemotherapy. Psychooncology. 18:187–194. 2009. View Article : Google Scholar :
|
|
45
|
Koenig HG, Shelp F, Goli V, et al:
Survival and health care utilization in elderly medical inpatients
with major depression. J Am Geriatr Soc. 37:599–606.
1989.PubMed/NCBI
|
|
46
|
Misono S, Weiss NS, Fann JR, et al:
Incidence of suicide in persons with cancer. J Clin Oncol.
26:4731–4738. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Michael Maes M, Meltzer HY, Stevens W, et
al: Natural killer cell activity in major depression: relation to
circulating natural killer cells, cellular indices of the immune
response, and depressive phenomenology. Prog Neuropsychopharmacol
Biol Psychiatry. 18:717–730. 1994. View Article : Google Scholar
|
|
48
|
Lutgendorf SK, Lamkin DM, DeGeest K, et
al: Depressed and anxious mood and T- cell cytokine expressing
populations in ovarian cancer patients. Brain Behav Immun.
22:890–900. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Saul AN, Oberyszyn TM, Daugherty C, et al:
Chronic stress and susceptibility to skin cancer. J Natl Cancer
Inst. 97:1760–1767. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Feng Z, Liu L, Zhang C, et al: Chronic
restraint stress attenuates p53 function and promotes
tumorigenesis. Proc Natl Acad Sci USA. 109:7013–7018. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hassan S, Karpova Y, Baiz D, et al:
Behavioral stress accelerates prostate cancer development in mice.
J Clin Invest. 123:874–886. 2013.PubMed/NCBI
|
|
52
|
Giese-Davis J, Collie K, Rancourt KM, et
al: Decrease in depression symptoms is associated with longer
survival in patient with metastatic breast cancer: a secondary
analysis. J Clin Oncol. 29:413–420. 2011. View Article : Google Scholar :
|
|
53
|
Li M, Fitzgerald P and Rodin G:
Evidence-based treatment of depression in patients with cancer. J
Clin Oncol. 30:1187–1196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Norman TR: The new antidepressants -
mechanisms of action. Aust Prescr. 22:106–108. 1999.
|
|
55
|
Laoutidis ZG and Mathiak K:
Antidepressants in the treatment of depression/depressive symptoms
in cancer patients: a systematic review and meta-analysis. BMC
Psychiatry. 13:1402013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lloyd-Williams M, Payne S, Reeve J and
Kolamunnage Dona R: Antidepressant medication in patients with
advanced cancer - an observational study. QJM. 106:995–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Olin J and Masand P: Psychostimulants for
depression in hospitalized cancer patients. Psychosomatics.
37:57–62. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Stefanczyk-Sapieha L, Oneschuk D and Demas
M: Intravenous ketamine “burst” for refractory depression in a
patient with advanced cancer. J Palliat Med. 11:1268–1271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Berman RM, Cappiello A, Anand A, et al:
Antidepressant effects of ketamine in depressed patients. Biol
Psychiatry. 47:351–354. 2001. View Article : Google Scholar
|
|
60
|
Caraci F, Crupi R, Drago F and Spina E:
Metabolic drug interactions between antidepressants and anticancer
drugs: focus on selective serotonin reuptake inhibitors and
hypericum extract. Curr Drug Metab. 12:570–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Borges S, Desta Z, Li L, et al:
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen
metabolism: implications for optimization of breast cancer
treatment. Clin Pharmacol Ther. 80:61–74. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Whitten DL, Myers SP, Hawrelak JA and
Wohlmuth H: The effect of St John’s wort extracts on CYP3A: a
systematic review of prospective clinical trials. Br J Clin
Pharmacol. 62:512–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yap KY, Tay WL, Chui WK and Chan A:
Clinically relevant drug interactions between anticancer drugs and
psychotropic agents. Eur J Cancer Care (Engl). 20:6–32. 2011.
View Article : Google Scholar
|
|
64
|
Sloman R: Relaxation and imagery for
anxiety and depression control in community patients with advanced
cancer. Cancer Nurs. 25:432–435. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Osborn RL, Demoncada AC and Feuerstein M:
Psychosocial interventions for depression, anxiety, and quality of
life in cancer survivors: meta-analyses. Int J Psychiatry Med.
36:13–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hopko DR, Armento ME, Robertson SM, et al:
Brief behavioural activation and problem-solving therapy for
depressed breast cancer patients: randomized trial. J Consult Clin
Psychol. 79:834–849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Feroes DL, Lane L, Ciarrochi J and
Blackledge JT: Acceptance and Commitment Therapy (ACT) for
improving the lives of cancer patients: a preliminary study.
Psychooncology. 22:459–464. 2013.
|
|
68
|
Barsevick AM, Sweeney C, Haney E and Chung
E: A systematic qualitative analysis of psychoeducational
interventions for depression in patients with cancer. Oncol Nurs
Forum. 29:73–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Craft LL, Vanlterson EH, Helenowski IB, et
al: Exercise effects on depressive symptoms in cancer survivors: a
systematic review and meta-analysis. Cancer Epidemiol Biomarkers
Prev. 21:3–19. 2012. View Article : Google Scholar :
|
